March 2 (Reuters) - Valeant Pharmaceuticals International Inc (NYSE:VRX) VRX.TO :
* Announces management change
* Deb Jorn has resigned as executive vice president, company group chairman,
effective immediately
* Says Ari Kellen, executive vice president and company group chairman will
oversee valeant's gastrointestinal business
* Eric Abramson, vice president dermatology & immunology marketing, has been
appointed general manager of U.S. dermatology business
* Source text for Eikon
* Further company coverage VRX.TO